AR076837A1 - Agentes antiinflamatorios como compuestos virostaticos. - Google Patents

Agentes antiinflamatorios como compuestos virostaticos.

Info

Publication number
AR076837A1
AR076837A1 ARP100101509A ARP100101509A AR076837A1 AR 076837 A1 AR076837 A1 AR 076837A1 AR P100101509 A ARP100101509 A AR P100101509A AR P100101509 A ARP100101509 A AR P100101509A AR 076837 A1 AR076837 A1 AR 076837A1
Authority
AR
Argentina
Prior art keywords
heterocycloalkyl
alkynylthio
cycloalkyl
alkenyl
alkanyl
Prior art date
Application number
ARP100101509A
Other languages
English (en)
Inventor
Manfred Groeppel
Daniel Vitt
Johann Leban
Roland Baumgartner
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076837(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of AR076837A1 publication Critical patent/AR076837A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Un inhibidor de la dihidroorotato deshidrogenasa caracterizado porque puede usarse en el tratamiento o la mejora de una enfermedad o una condicion médica causadas por una infeccion de virus de ADN de cadena doble (virus de ADNcd), virus de ARN de cadena simple en el sentido positivo (virus de (+)ARNcs), virus de ARN de cadena simple en el sentido negativo (virus de (-)ARNcs), virus de ADN de cadena doble (ADNcd), virus de ARN de cadena simple que usan un intermediario de ADN para replicarse (virus de ARNcs-RT), virus de ADN de cadena doble que usan un intermediario de ARN durante la replicacion del genoma (virus de ADNcd-RT), donde el inhibidor de la dihidroorotato deshidrogenasa no es leflunomida o un metabolito de ésta. Reivindicacion 5: Un inhibidor de la dihidroorotato deshidrogenasa que puede usarse en el tratamiento o la mejora de una enfermedad o una condicion médica causadas por una infeccion viral de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque el inhibidor de la dihidroorotato deshidrogenasa es un compuesto de la formula general (1) o un derivado funcional desde el punto de vista fisiologico o una sal tolerable desde el punto de vista farmacologico de éste, donde A es un anillo hidrocarbonado aromático o no aromático de 5 o 6 miembros donde opcionalmente uno o más de los átomos de carbono se reemplazan por un grupo X, donde X se selecciona en forma independiente entre el grupo que consiste en S, O, N, NR4, SO2 y SO; L es una union simple o NH; D es O, S, SO2, NR4, o CH2; Z1 es O, S, o NR5; Z2 es O, S, o NR5; R1 en forma independiente representa H, halogeno, haloalcanilo, haloalquenilo, haloalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, -CO2Rö , -SO3H, -OH, - CONR*Rö, -CRöO, SO2NR*Rö, -NO2, -SO2-Rö, SO-R*, CN, alcaniloxi, alqueniloxi, alquiniloxi, alcaniltio, alqueniltio, alquiniltio, arilo, -NRö-CO2-R', -NRö-CO-R*, -NRö-SO2-R', -O-CO-R*, -O-CO2-R*, -O-CO-NR*Rö; cicloalquilo, heterocicloalquilo, alcanilamino, alquenilamino, alquinilamino, hidroxialcanilamino, hidroxialquenilamino, hidroxialquinilamino, -SH, heteroarilo, alcanilo, alquenilo o alquinilo; R* en forma independiente representa H, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, aminoalcanilo, aminoalquenilo, aminoalquinilo, alcaniloxi, alqueniloxi, alquiniloxi, -OH, -SH, alcaniltio, alqueniltio, alquiniltio, hidroxialcanilo, hidroxialquenilo, hidroxialquinilo, haloalcanilo, haloalquenilo, haloalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, arilo o heteroarilo; R' en forma independiente representa H, -CO2Rö, -CONRöRö', -CRöO, -SO2NRö, -NRö-CO-haloalcanilo, haloalquenilo, haloalquinilo, -NO2, -NRö -SO2-haloalcanilo, haloalquenilo, haloalquinilo, -NRö-SO2-alcanilo, -NRö-SO2-alquenilo, -NRö-SO2-alquinilo, -SO2-alcanilo, -SO2-alquenilo, -SO2-alquinilo, -NRö-CO-alcanilo, -NRö-CO-alquenilo, -NRö-CO-alquinilo, -CN, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, aminoalcanilo, aminoalquenilo, aminoalquinilo, alcanilamino, alquenilamino, alquinilamino, alcaniloxi, alqueniloxi, alquiniloxi, -cicloalquiloxi, - OH, -SH, alcaniltio, alqueniltio, alquiniltio, hidroxialcanilo, hidroxialquenilo, hidroxialquinilo, hidroxialcanilamino, hidroxialquenilamino, hidroxialquinilamino, halogeno, haloalcanilo, haloalquenilo, haloalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, arilo, aralquilo o heteroarilo; Rö en forma independiente representa hidrogeno, haloalcanilo, haloalquenilo, haloalquinilo, hidroxialcanilo, hidroxialquenilo, hidroxialquinilo, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, aminoalcanilo, aminoalquenilo o aminoalquinilo; Rö' en forma independiente representa H o alcanilo; R2 es H o OR6, NHR7, NR7OR7; o R2 junto con el átomo de nitrogeno que se une a R8 forma un anillo heterocíclico de entre 5 y 7 miembros, preferentemente de entre 5 y 6 miembros donde R2 es -[CH2]s y R8 se encuentra ausente; R3 es H, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, alcaniloxi, alqueniloxi, alquiniloxi, -O-arilo; -O-cicloalquilo, -O-heterocicloalquilo, halogeno, aminoalcanilo, aminoalquenilo, aminoalquinilo, alcanilamino, alquenilamino, alquinilamino, hidroxilamino, hidroxilalcanilo, hidroxilalquenilo, hidroxilalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, heteroarilo, alcaniltio, alqueniltio, alquiniltio, -S-arilo; -S-cicloalquilo, -S-heterocicloalquilo, aralquilo, haloalcanilo, haloalquenilo o haloalquinilo; R4 es H, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo o heteroarilo; R5 es H, OH, alcaniloxi, alqueniloxi, alquiniloxi, O-arilo, alcanilo, alquenilo, alquinilo o arilo; R6 es H, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, aralquilo, alcaniloxialcanilo, alcaniloxialquenilo, alcaniloxialquinilo, alqueniloxialcanilo, alqueniloxialquenilo, alqueniloxialquinilo, alquiniloxialcanilo, alquiniloxialquenilo, alquiniloxialquinilo, acilalcanilo, (aciloxi)alcanilo, (aciloxi)alquenilo, (aciloxi)alquinilo acilo, (aciloxi)alcanildiéster no simétrico, (aciloxi)alquenildiéster no simétrico, (aciloxi) alquinildiéster no simétrico, o dialcanilfosfato, dialquenilfosfato o dialquinilfosfato; R7 es H, OH, alcanilo, alquenilo, alquinilo, arilo, alcaniloxi, alqueniloxi, alquiniloxi, -O-arilo, cicloalquilo, heterocicloalquilo, o -O-cicloalquilo, -O-heterocicloalquilo; R8 es hidrogeno, alcanilo, alquenilo o alquinilo; E es un grupo alcanilo, alquenilo, alquinilo, arilo, heteroarilo, heterocicloalquilo o cicloalquilo o un sistema de anillos fusionado bicíclico o tricíclico donde un anillo fenilo está fusionado a uno o dos anillos cicloalquilo o heterocicloalquilo monocíclicos o un anillo cicloalquilo o heterocicloalquilo bicíclico, o donde dos anillos fenilo están fusionados a un anillo cicloalquilo o heterocicloalquilo monocíclico, donde los anillos cicloalquilo y heterocicloalquilo monocíclicos y bicíclicos son como se definen en la presente, y donde todos los grupos mencionados pueden estar opcionalmente sustituidos con uno o más sustituyentes R'; Y es hidrogeno, halogeno, haloalcanilo, haloalquenilo, haloalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, alcanilo, alquenilo, alquinilo, arilo, heteroarilo, heterocicloalquilo o cicloalquilo o un sistema de anillos fusionado bicíclico o tricíclico donde un anillo fenilo está fusionado a uno o dos anillos cicloalquilo o heterocicloalquilo monocíclicos o un anillo cicloalquilo o heterocicloalquilo bicíclico, o donde dos anillos fenilo están fusionados a un anillo cicloalquilo o heterocicloalquilo monocíclico, y donde todos los grupos mencionados pueden estar opcionalmente sustituidos con uno o más sustituyentes R', o Y es formula (2) donde R1, X, A, Z1, Z2, R8, R2, E y p son como se definen en la presente; m es 0 o 1; n es 0 o 1; p es 0 o 1; q es 0 o 1; r es 0 o 1; s es entre 0 y 2; y t es entre 0 y 3.
ARP100101509A 2009-05-04 2010-05-04 Agentes antiinflamatorios como compuestos virostaticos. AR076837A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17525509P 2009-05-04 2009-05-04
EP09159358 2009-05-04

Publications (1)

Publication Number Publication Date
AR076837A1 true AR076837A1 (es) 2011-07-13

Family

ID=43030861

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101509A AR076837A1 (es) 2009-05-04 2010-05-04 Agentes antiinflamatorios como compuestos virostaticos.

Country Status (16)

Country Link
US (1) US8354433B2 (es)
EP (1) EP2427186B1 (es)
CN (1) CN102458389A (es)
AR (1) AR076837A1 (es)
AU (1) AU2010244462B2 (es)
CA (1) CA2761130C (es)
CO (1) CO6450622A2 (es)
ES (1) ES2909738T3 (es)
MX (1) MX2011011733A (es)
NZ (1) NZ596014A (es)
PE (1) PE20120898A1 (es)
SG (1) SG175854A1 (es)
TW (1) TWI530286B (es)
UY (1) UY32605A (es)
WO (1) WO2010128050A2 (es)
ZA (1) ZA201108131B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108760C2 (uk) * 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
WO2013009678A2 (en) * 2011-07-08 2013-01-17 Indiana University Research And Technology Corporation Compositions and methods for the treatment of norovirus infection
WO2015154820A1 (en) * 2014-04-11 2015-10-15 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
MX2016014634A (es) 2014-05-08 2017-04-10 Panoptes Pharma Ges M B H Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
WO2020225330A1 (en) * 2019-05-07 2020-11-12 Universität Hamburg Dhodh inhibitors and their use as antiviral agents
AU2021260040A1 (en) * 2020-04-21 2022-11-17 Immunic Ag Vidofludimus for use in the treatment or prevention of viral diseases
JP2023543969A (ja) * 2020-08-31 2023-10-19 アスラン ファーマスーティカルズ ピーティーイー エルティーディー ウイルス感染の治療及び／又は予防
JPWO2022196236A1 (es) * 2021-03-18 2022-09-22
AU2022253683A1 (en) 2021-04-09 2023-10-26 Immunic Ag Deuterated dhodh inhibitors
EP4119138A1 (en) * 2021-07-12 2023-01-18 Universität Hamburg Dhodh inhibitors and their use as antiviral agents
IL313501A (en) 2021-12-23 2024-08-01 Immunic Ag DHODH INHIBITORS CONTAINING CARBOXYLIC ACID BIOISOSTERE
US20230278979A1 (en) * 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
AU2023230874A1 (en) * 2022-03-09 2024-09-19 Kiora Pharmaceuticals Gmbh Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor
WO2023232884A1 (en) 2022-06-01 2023-12-07 Immunic Ag Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof
CN116803387A (zh) * 2023-07-25 2023-09-26 徐州医科大学 Vidofludimus在制备戊型肝炎药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
WO2001024785A2 (en) * 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2003006424A1 (en) * 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056797A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056746A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581478A1 (en) * 2002-12-23 2005-10-05 4Sc Ag Dhodh-inhibitors and method for their identification
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
EP2427186A2 (en) 2012-03-14
PE20120898A1 (es) 2012-08-24
CN102458389A (zh) 2012-05-16
CO6450622A2 (es) 2012-05-31
US8354433B2 (en) 2013-01-15
AU2010244462B2 (en) 2015-07-02
NZ596014A (en) 2013-06-28
ZA201108131B (en) 2012-07-25
CA2761130C (en) 2017-03-28
WO2010128050A2 (en) 2010-11-11
UY32605A (es) 2010-12-31
AU2010244462A1 (en) 2011-11-17
WO2010128050A3 (en) 2011-05-05
CA2761130A1 (en) 2010-11-11
ES2909738T3 (es) 2022-05-10
EP2427186B1 (en) 2022-01-12
TWI530286B (zh) 2016-04-21
SG175854A1 (en) 2011-12-29
MX2011011733A (es) 2012-02-01
US20100280081A1 (en) 2010-11-04
TW201043228A (en) 2010-12-16

Similar Documents

Publication Publication Date Title
AR076837A1 (es) Agentes antiinflamatorios como compuestos virostaticos.
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
CY1119880T1 (el) Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
AR082937A1 (es) Fosforamidatos de nucleosido
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
CY1114647T1 (el) Παραγωγο (αζα)και χρηση αυτου για ιατρικους σκοπους
RU2014143250A (ru) Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
BR112015021336A2 (pt) compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
JP2015517555A5 (es)
EA201391264A1 (ru) 1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
JP2015521189A5 (es)
CO6331439A2 (es) 1-2 bicíclicos pirimidinona carboxamida como inhibidores de la integrasa del virus de inmunodeficiencia humana
CN103619356A (zh) 肽寡核苷酸缀合物
EA200702445A1 (ru) Соединения тиазола и способы их применения
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
EA201201277A1 (ru) Кристаллические соли эффективного ингибитора вируса гепатита с
JP2016508145A5 (es)
BR112014006559A2 (pt) derivados do ácido betulínico com atividade antiviral
JP2015512254A (ja) オリゴヌクレオチドアナログのボロン酸結合体
RU2014120421A (ru) Производные гетероарилгидроксамовой кислоты и их применение при лечении, облегчении течения или профилактике вирусных заболеваний

Legal Events

Date Code Title Description
FB Suspension of granting procedure